cisapride has been researched along with Genetic Predisposition in 3 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Incidents of adverse cardiac drug reactions are more common in patients with preexisting heart disease than the general population." | 1.39 | Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. ( Bers, DM; Diecke, S; Gong, T; Knowles, JW; Lan, F; Lee, AS; Liang, P; Nguyen, PK; Robbins, RC; Sallam, K; Sanchez-Freire, V; Wang, PJ; Wang, Y; Wu, JC, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, P | 1 |
| Lan, F | 1 |
| Lee, AS | 1 |
| Gong, T | 1 |
| Sanchez-Freire, V | 1 |
| Wang, Y | 1 |
| Diecke, S | 1 |
| Sallam, K | 1 |
| Knowles, JW | 1 |
| Wang, PJ | 1 |
| Nguyen, PK | 1 |
| Bers, DM | 1 |
| Robbins, RC | 1 |
| Wu, JC | 1 |
| Romero, L | 1 |
| Trenor, B | 1 |
| Yang, PC | 1 |
| Saiz, J | 1 |
| Clancy, CE | 1 |
| Makita, N | 1 |
| Horie, M | 1 |
| Nakamura, T | 1 |
| Ai, T | 1 |
| Sasaki, K | 1 |
| Yokoi, H | 1 |
| Sakurai, M | 1 |
| Sakuma, I | 1 |
| Otani, H | 1 |
| Sawa, H | 1 |
| Kitabatake, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study[NCT02738749] | 450 participants (Anticipated) | Interventional | 2014-06-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for cisapride and Genetic Predisposition
| Article | Year |
|---|---|
Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Topics: Action Potentials; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic, Familial; Cell Differentia | 2013 |
In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
Topics: Action Potentials; Anti-Arrhythmia Agents; Astemizole; Cisapride; Computer Simulation; Gene Expressi | 2014 |
Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation.
Topics: Aged; Amino Acid Sequence; Base Sequence; Cell Line; Cisapride; Electric Conductivity; Electrocardio | 2002 |